Deb, Arijita
Podmore, Bélène
Barnett, Rosemarie
Beier, Dominik
Galetzka, Wolfgang
Qizilbash, Nawab
Haeckl, Dennis
Boellinger, Timo
Johnson, Kelly D.
Weiss, Thomas
Funding for this research was provided by:
Merck Sharp and Dohme
Article History
Received: 29 November 2021
Accepted: 14 September 2022
First Online: 28 September 2022
Declarations
:
: De-identified SHI data were used for this research. The use of such data is not subject to ethics committee approval in Germany. The study obtained approval from the internal InGef Scientific Research Group which considers both ethical and scientific aspects of the intended study and has waived the need for informed consent. The study was carried out in accordance with relevant guidelines.
: Not applicable.
: This research was sponsored and funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (MSD). OXON Epidemiology, an independent contract research organization, was contracted by MSD to design and conduct the study in collaboration with WIG2. InGef acted as subcontractor and received funding from WIG2 for the execution of the study. All authors declare financial and non-financial conflicts of interest. KDJ and TW are employed by MSD USA, and TB is employed by MSD in Germany (Levelingstr. 4a, 81673 München). AD was employed by MSD USA at the time of the study. BP, RB and NQ are employed by OXON Epidemiology. DH is employed by WIG2. DB is employed by InGef and WG was employed by InGef at the time of this study.